News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

This important study provides interesting insights into the mechanisms of action of adjuvants. It shows that adjuvants, MPLA and CpG especially, modulate the peptide repertoires presented on the ...

The speakers explored adjuvant endocrine therapies, prognostic and predictive factors for clinical decision-making, and the unique challenges of optimising treatment for older patients, underscoring ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

However, 2 recent clinical trials, National Surgical Adjuvant Breast and Bowel Project C-07 and MOSAIC, have provided more insight into defining the optimal treatment approach. With the ...

for breast cancer were updated this month to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients breast cancer. According to a press ...

"The Phase III NATALEE trial demonstrated a noteworthy 25.1% reduction in the risk of recurrence among patients with HR+/HER2- stage II and III early breast cancer receiving adjuvant Kisqali ...

the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for breast cancer were updated to recommend ribociclib (Kisqali ®) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant ...